SCHEMBL4699871

SCHEMBL4699871

O=C(O)c1cccc(-c2nnc(Cc3c(Cl)cncc3Cl)c3ccc(OC(F)F)cc23)c1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 9/20 0.60
PDE4B Q07343 9/20 0.60
PDE4C Q08493 9/20 0.60
PDE4D Q08499 9/20 0.60
MRGPRX4 Q96LA9 1/20 0.40
NR1H4 Q96RI1 3/20 0.37
LIFR P42702 1/20 0.37
PLAU P00749 1/20 0.37
MAP2K4 P45985 1/20 0.35
THRA P10827 1/20 0.35
THRB P10828 1/20 0.35
CSNK2A2 P19784 1/20 0.35
CSNK2B P67870 1/20 0.35
GPR84 Q9NQS5 2/20 0.34
MAPK8 P45983 1/20 0.34
MAPK10 P53779 1/20 0.34
MAPK14 Q16539 1/20 0.34
HSD17B13 Q7Z5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4699816 0.89 PDE4A (0.76) PDE4APDE4BPDE4CPDE4DMRGPRX4
SCHEMBL4701819 0.78 PDE4A (0.77) PDE4APDE4BPDE4CPDE4D
SCHEMBL4703782 0.78 PDE4A (0.53) PDE4APDE4BPDE4CPDE4D
SCHEMBL6683024 0.76 PDE4A (0.74) PDE4APDE4BPDE4CPDE4DTHRA
SCHEMBL6681398 0.76 PDE4A (0.72) PDE4APDE4BPDE4CPDE4DPLAU
SCHEMBL6586085 0.75 PDE4A (1.00) PDE4APDE4BPDE4CPDE4D
SCHEMBL6686882 0.75 PDE4A (0.79) PDE4APDE4BPDE4CPDE4D
SCHEMBL6683381 0.75 PDE4A (0.71) PDE4APDE4BPDE4CPDE4DNR1H4
SCHEMBL6681005 0.74 PDE4A (0.70) PDE4APDE4BPDE4CPDE4D
SCHEMBL6683041 0.74 PDE4A (0.70) PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1581229-B1 PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS ZAMBON SPA (IT) 2008-03-12 EP claimed
US-20060166996-A1 Phthalazine derivatives as phosphodiesterase 4 inhibitors ZAMBON GROUP S.P.A. (IT) 2006-07-27 US claimed
EP-1581229-A1 PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS ZAMBON GROUP S.p.A. (IT) 2005-10-05 EP claimed
WO-2004056366-A1 PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS ZAMBON GROUP S.P.A. (IT) 2004-07-08 WO claimed
EP-1581229-B1 PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS ZAMBON SPA (IT) 2008-03-12 EP disclosed
US-20060166996-A1 Phthalazine derivatives as phosphodiesterase 4 inhibitors ZAMBON GROUP S.P.A. (IT) 2006-07-27 US disclosed
EP-1581229-A1 PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS ZAMBON GROUP S.p.A. (IT) 2005-10-05 EP disclosed
WO-2004056366-A1 PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS ZAMBON GROUP S.P.A. (IT) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060166996-A1 Phthalazine derivatives as phosphodiesterase 4 inhibitors PDE4A, PDE5A, PDE2A PDE4A 1/4885PDE4B 6/4885PDE4C 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.